Bluebird Biotech Moves Further for New and Better Future

Bluebird bio, situated in Massachusetts, determined it was time for a new headquarters because many of its employees were working from home and others had gone for a new spinoff venture. A move from Kendall Square in Cambridge, three miles north, to Assembly Row in Somerville, along the Mystic River, would not only meet the firm’s changing needs, but will also save nearly $120 million in overhead over the next six years, according to the company.

The relocation will take place next spring in a 61,000 square foot space that will house 425 employees. While said it was developing a “biotech cluster” at Assembly Row, Puma, the worldwide sportswear firm, announced on Thursday that it had opened its North American headquarters there in a 150,000-square-foot location. As hybrid work “is here to stay,” Bluebird stated its new digs will “enable a remote work style” and allow for “greater engagement and productivity.” The corporation will keep its Cambridge lab location until 2023.

“As we navigated through the COVID-19 epidemic and re-established ourselves as a firm focused on pursuing curative gene therapies over the last 18 months, we’ve revolutionised the way we work and live.” Bluebird, which is 11 years old, announced earlier this year that its oncology arm would be spun out as 2seventy bio. The spinoff was completed this week by the corporation. 2seventy bio is led by Bluebird previous CEO Nick Leschly, with Andrew Obenshain, the company’s former rare illness chief, taking over as the CEO of the company.